$NSPR
InspireMD, Inc. Stock $nspr

$nspr Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224030265 Filed on August 05, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$1.810M	$1.739M
YoY Change	16.32%	5.46%
Cost Of Revenue	$1.396M	$1.408M
YoY Change	24.87%	21.59%
Gross Profit	$414.0K	$331.0K
YoY Change	-5.48%	-32.59%
Gross Profit Margin	22.87%	19.03%
Selling, General & Admin	$4.961M	$5.190M
YoY Change	25.06%	36.11%
% of Gross Profit	1198.31%	1567.98%
Research & Development	$3.915M	$3.401M
YoY Change	85.55%	70.65%
% of Gross Profit	945.65%	1027.49%
Depreciation & Amortization	$70.00K	$66.00K
YoY Change	14.75%	13.79%
% of Gross Profit	16.91%	19.94%
Operating Expenses	$8.876M	$8.591M
YoY Change	46.06%	47.97%
Operating Profit	-$8.462M	-$8.260M
YoY Change	50.06%	55.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$572.0K	$351.0K
YoY Change	24.08%	47.48%
Pretax Income	-$7.890M	-$7.909M
YoY Change	52.38%	55.78%
Income Tax
% Of Pretax Income
Net Earnings	-$7.890M	-$7.909M
YoY Change	52.38%	55.78%
Net Earnings / Revenue	-435.91%	-454.8%
Basic Earnings Per Share	-$0.16	-$0.22
Diluted Earnings Per Share	-$0.16	-$0.22
COMMON SHARES
Basic Shares Outstanding	25.71M shares	24.93M shares
Diluted Shares Outstanding	48.37M shares	35.88M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.40M	$47.16M
YoY Change	-6.04%	0.36%
Cash & Equivalents	$15.82M	$28.39M
Short-Term Investments	$24.58M	$18.78M
Other Short-Term Assets	$1.276M	$717.0K
YoY Change	168.07%	1180.36%
Inventory	$2.445M	$2.206M
Prepaid Expenses	$1.276M	$717.0K
Receivables	$1.530M	$1.307M
Other Receivables	$741.0K	$450.0K
Total Short-Term Assets	$46.39M	$51.84M
YoY Change	-0.71%	2.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.946M	$1.595M
YoY Change	114.55%	-29.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$996.0K	$964.0K
YoY Change	17.59%	12.49%
Total Long-Term Assets	$4.087M	$3.816M
YoY Change	24.15%	22.39%
TOTAL ASSETS
Total Short-Term Assets	$46.39M	$51.84M
Total Long-Term Assets	$4.087M	$3.816M
Total Assets	$50.48M	$55.66M
YoY Change	0.92%	3.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.305M	$927.0K
YoY Change	117.5%	-80.8%
Accrued Expenses	$1.437M	$1.149M
YoY Change	55.18%	54.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.265M	$6.965M
YoY Change	54.9%	44.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.865M	$1.931M
YoY Change	-10.03%	-3.26%
Total Long-Term Liabilities	$1.865M	$1.931M
YoY Change	-10.03%	-3.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.265M	$6.965M
Total Long-Term Liabilities	$1.865M	$1.931M
Total Liabilities	$9.130M	$8.896M
YoY Change	35.0%	30.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$244.3M	-$236.4M
YoY Change	13.07%	12.1%
Common Stock	$3.000K	$3.000K
YoY Change	50.0%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.35M	$46.76M
YoY Change
Total Liabilities & Shareholders Equity	$50.48M	$55.66M
YoY Change	0.92%	3.77%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$7.890M	-$7.909M
YoY Change	52.38%	55.78%
Depreciation, Depletion And Amortization	$70.00K	$66.00K
YoY Change	14.75%	13.79%
Cash From Operating Activities	-$5.700M	-$4.354M
YoY Change	41.12%	30.95%
INVESTING ACTIVITIES
Capital Expenditures	$421.0K	$475.0K
YoY Change	338.54%	955.56%
Acquisitions
YoY Change
Other Investing Activities	-$5.503M	$5.981M
YoY Change	-184.92%	-122.28%
Cash From Investing Activities	-$5.924M	$5.506M
YoY Change	-192.79%	-120.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-965.0K	17.85M
YoY Change	-24225.0%	-52.43%
NET CHANGE
Cash From Operating Activities	-5.700M	-4.354M
Cash From Investing Activities	-5.924M	5.506M
Cash From Financing Activities	-965.0K	17.85M
Net Change In Cash	-12.59M	19.01M
YoY Change	-635.93%	159.72%
FREE CASH FLOW
Cash From Operating Activities	-$5.700M	-$4.354M
Capital Expenditures	$421.0K	$475.0K
Free Cash Flow	-$6.121M	-$4.829M
YoY Change	48.03%	43.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv
	dei	Entity Address Country EntityAddressCountry	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6744832
	dei	City Area Code CityAreaCode	(888)
	dei	Local Phone Number LocalPhoneNumber	776-6204
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	NSPR
	NSPR	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised		usd
CY2024Q2	NSPR	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits		usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	NSPR	Proceeds From Matured Marketable Securities ProceedsFromMaturedMarketableSecurities		usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2024Q2	NSPR	Marketable Securities Maturities After One Year Through Two Years Fair Value MarketableSecuritiesMaturitiesAfterOneYearThroughTwoYearsFairValue		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q4	NSPR	Issuance Costs Not Yet Paid IssuanceCostsNotYetPaid		usd
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25706671	shares
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28385000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9640000	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18778000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1307000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1804000	usd
CY2024Q2	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	450000	usd
CY2023Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	648000	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	717000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	578000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	2206000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	51843000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	44159000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1595000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1060000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1257000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1473000	usd
CY2024Q2	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	964000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	951000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	3816000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3484000	usd
CY2024Q2	us-gaap	Assets Assets	55659000	usd
CY2023Q4	us-gaap	Assets Assets	47643000	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	927000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	939000	usd
CY2024Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6038000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5081000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6965000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6020000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	786000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1038000	usd
CY2024Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1145000	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1084000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1931000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2122000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	8896000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8142000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25196479	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25196479	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21841215	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21841215	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	283202000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	261000000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-236442000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-221501000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46763000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39501000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55659000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47643000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3250000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2888000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2627000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2024000	usd
	us-gaap	Gross Profit GrossProfit	623000	usd
	us-gaap	Gross Profit GrossProfit	864000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6026000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3836000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2682000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1680000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7589000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5044000	usd
	us-gaap	Operating Expenses OperatingExpenses	16297000	usd
	us-gaap	Operating Expenses OperatingExpenses	10560000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15674000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9696000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	733000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	363000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14941000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9333000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35877926	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35877926	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21074187	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21074187	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35060451	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35060451	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14619622	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14619622	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9333000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4635000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37534000	usd
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	4270	shares
	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	1219000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46813000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13426000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5077000	usd
CY2023Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4635000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37534000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37534000	usd
CY2023Q2	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	930000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46813000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39501000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14941000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	12621090	shares
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000000	usd
	NSPR	Stock Issued During Period Value Stock Warrants Exercised And Common Stock StockIssuedDuringPeriodValueStockWarrantsExercisedAndCommonStock	16854000	usd
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	112382	shares
	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	5349000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46763000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	35087000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	35087000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-7909000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	12621090	shares
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000000	usd
CY2024Q2	NSPR	Stock Issued During Period Value Stock Warrants Exercised And Common Stock StockIssuedDuringPeriodValueStockWarrantsExercisedAndCommonStock	16854000	usd
CY2024Q2	NSPR	Stock Issued During Period Value Stock Warrants Exercised And Common Stock StockIssuedDuringPeriodValueStockWarrantsExercisedAndCommonStock	16854000	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	37292	shares
CY2024Q2	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	2731000	usd
CY2024Q2	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	2731000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46763000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46763000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14941000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9333000	usd
	us-gaap	Depreciation Depreciation	135000	usd
	us-gaap	Depreciation Depreciation	113000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	8000	usd
	NSPR	Loss Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	-34000	usd
	NSPR	Loss Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	-42000	usd
	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities	435000	usd
	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities	-21000	usd
	NSPR	Change In Liability For Employees Rights Upon Retirement ChangeInLiabilityForEmployeesRightsUponRetirement	-61000	usd
	NSPR	Change In Liability For Employees Rights Upon Retirement ChangeInLiabilityForEmployeesRightsUponRetirement	-31000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-14000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-23000	usd
	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	55000	usd
	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	60000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5349000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1219000	usd
	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits	-40000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	139000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-599000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-497000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	436000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-198000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	99000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	100000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	68000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-12000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	109000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-24000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-349000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9418000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8156000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	670000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	9000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1960000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28838000	usd
	NSPR	Proceeds From Matured Marketable Securities ProceedsFromMaturedMarketableSecurities	13000000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	12000000	usd
	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	47000	usd
	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	43000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10323000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22442000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	17854000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	37534000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37534000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-23000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6913000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4632000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11545000	usd
	us-gaap	Stock Issued1 StockIssued1	1000000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zAevbIwcSmG" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_824_zvcRJl5og59b">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company markets its products through distributors in international markets, mainly in Europe.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date of issuance of the condensed consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>War against Hamas</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, Israel was attacked by a terrorist organization and entered a state of war. In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen) As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company operations, including its production facility, are located in Israel. Currently, such activities in Israel remain largely unaffected. During the six months ended June 30, 2024, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_808_eus-gaap--BasisOfAccounting_zU22M5MZc6b3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_820_zbufWWSX3ck8">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements for the year ended December 31, 2023. In the opinion of the company, all adjustments considered necessary for a fair statement of the results of the interim periods reported herein have been included (consisting only of normal recurring adjustments). These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 5, 2024. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of results that could be expected for the entire fiscal year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Securities Borrowed Fair Value Disclosure SecuritiesBorrowedFairValueDisclosure	18137000	usd
CY2023Q4	us-gaap	Securities Borrowed Fair Value Disclosure SecuritiesBorrowedFairValueDisclosure	28727000	usd
CY2024Q2	NSPR	Marketable Securities Maturities Within One Year Fair Value MarketableSecuritiesMaturitiesWithinOneYearFairValue	18778000	usd
CY2023Q4	NSPR	Marketable Securities Maturities Within One Year Fair Value MarketableSecuritiesMaturitiesWithinOneYearFairValue	24523000	usd
CY2023Q4	NSPR	Marketable Securities Maturities After One Year Through Two Years Fair Value MarketableSecuritiesMaturitiesAfterOneYearThroughTwoYearsFairValue	4860000	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18778000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1960000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28838000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13000000	usd
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	122000	usd
	NSPR	Changes In Fair Value Marketable Securities ChangesInFairValueMarketableSecurities	557000	usd
	NSPR	Changes In Fair Value Marketable Securities ChangesInFairValueMarketableSecurities	-21000	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	18778000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	28817000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	40479588	shares
CY2024Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	155000000	shares
CY2024Q2	NSPR	Capital Stock Par Or Stated Value Per Share CapitalStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15385212	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2905615	shares
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	124000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	210000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	537000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	562000	usd
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1545000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1334000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	2206000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106000	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1656000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2188000	usd
CY2024Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	384000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	287000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1149000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1115000	usd
CY2024Q2	NSPR	Issuance Costs Not Yet Paid IssuanceCostsNotYetPaid	1000000	usd
CY2024Q2	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	1128000	usd
CY2023Q4	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	744000	usd
CY2024Q2	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	538000	usd
CY2023Q4	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	557000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	183000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	190000	usd
CY2024Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6038000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5081000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-030265-index-headers.html	Edgar Link	pending
0001493152-24-030265-index.html	Edgar Link	pending
0001493152-24-030265.txt	Edgar Link	pending
0001493152-24-030265-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nspr-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
nspr-20240630_cal.xml	Edgar Link	unprocessable
nspr-20240630_def.xml	Edgar Link	unprocessable
nspr-20240630_lab.xml	Edgar Link	unprocessable
nspr-20240630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NSPR
InspireMD, Inc. Stock $nspr

2024 Q3 Form 10-Q Financial Statement

#000149315224030265 Filed on August 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR InspireMD, Inc. Stock $nspr

2024 Q3 Form 10-Q Financial Statement

#000149315224030265 Filed on August 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR
InspireMD, Inc. Stock $nspr